ADDED
As of March 24, 2026, 38,664,571 shares of the registrant s common stock, par value $ .0001 per share, were issued and outstanding.
is a medical device sales and distribution enterprise focused on the marketing and distribution of syringe products and related drug-delivery systems.
We previously designed and manufactured a portfolio of conventional and safety syringes for clinical, pharmaceutical, and specialty applications and continues to market certain remaining inventory to hospitals, clinics, healthcare providers, and medical supply organizations in both domestic and international markets.
We plan to expand its distribution platform by representing established third-party manufacturers of complementary and synergistic medical products serving a common customer base.
Sharps Technology is committed to maintaining compliance with all applicable regulatory and quality standards governing the marketing and distribution of medical devices, including those established by the U.S.
Food and Drug Administration (FDA) and comparable international authorities.
On August 23, 2025, we adopted a digital asset treasury strategy focused on accumulating Solana ( SOL ), the native digital asset of the Solana blockchain.
Our Solana Treasury Strategy On August 28, 2025, upon the closing of our Private Investment in Public Equity Offering ( PIPE ) of approximately $400 million, our Board has adopted a treasury policy (the Treasury Policy ), the material terms of which are set forth below, under which the principal holding in our treasury reserve on the balance sheet will be allocated to SOL.
Although we reserve the right to accumulate other forms of digital assets in the future, we currently only own SOL, USDC and USDT, with the vast majority of such digital assets being SOL.
Upon the closing of the PIPE, we purchased and continue to hold over 2,000,000 SOL, including staking rewards, representing almost all of the capital raised in that offering.
REMOVED
As of March 25, 2025, 16,333,897 shares of the registrant s common stock, par value $ .0001 per share, were issued and outstanding.
is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry.
The Company s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features.
Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment.
We were initially incorporated under the laws of the State of Wyoming on December 16, 2017.
Prior to March 22, 2022, we were a Wyoming corporation and on March 22, 2022, we reincorporated as a Nevada corporation pursuant to a merger into a newly formed Nevada corporation which was approved by our board of directors and the holders of the majority of our outstanding shares of common stock Sharps was incorporated to purchase, develop, and commercialize a body of intellectual property resulting in a family of smart safety syringe products and innovative drug delivery devices.
Sharps closed the acquisition of this intellectual property in the fourth quarter of 2017.
The intellectual property we purchased consisted of issued patent and patent files, new designs and iterations, samples, regulatory files, manufacturing files, product testing files, and market research files relating to such safety syringe products.
In June 2020, we entered into an asset/share purchase agreement with Safegard Medical Kft.
( Safegard ) and certain other parties, and in August 2020, October 2020, and July 2021, we entered into amendments to this agreement (as amended, the Safegard Agreement ).